Fasenra Pediatric Japan Post-Marketing Study(PMS)

Study identifier:D3250C00100

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

FASENRA® Subcutaneous Injection 30 mg / 10mg Syringe Protocol of Specific drug use result study for pediatric patients

Medical condition

Bronchial Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

40

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 31 Jul 2024
Estimated Primary Completion Date: 17 Mar 2027
Estimated Study Completion Date: 17 Mar 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria